Connaught's Typhim Vi Launched In USA
Connaught Laboratories has launched its Typhim Vi single-dose typhoid vaccine onto the market in the USA. It is the first vaccine to become available for the prevention of typhoid fever in patients aged two years or older in the USA, and is given in a single, 0.5ml intramuscular dose.
Trials in Nepal have indicated that the protective efficacy of the vaccine is 74% over a 20-month follow-up period, and similar studies in South Africa suggest an overall protective efficacy of 55% over three years. The vaccine is intended for use by travellers to areas where the disease is endemic or epidemic. Connaught says the singe-dose will increase the likelihood of patient compliance compared to the existing oral or injectable multidose, alternate day regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze